Sera Prognostics SERA 深 沪
交易中 09-16 10:33:44 美东时间
1.99
0.000
0.00%
华盛通- 最 高2.00
- 今 开2.00
- 成交量 46股
- 最 低 2.00
- 昨 收 1.99
- 总市值 7850.44万
- 52周最高 3.95
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.56
- 委 比 0.00%
- 总股本 3944.95万
- 历史最高 15.50
- 量 比 0.01
- 振 幅 0.00%
- 历史最低 1.10
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sera Prognostics appoints Scott Gleason as CFO, effective Aug. 31
Sera Prognostics (SERA) announced on Wednesday that Scott Gleason will become CFO, effective August 31, 2026. Gleason has more than 25 years of healthcare, diagnostics, and capital markets experience ...
08-20 04:38
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnanc...
08-20 04:30
Sera Prognostics 2026财年第二季度业绩电话会议：伊利诺伊州医疗补助计划覆盖与PreTRM商业化推进
得益于伊利诺伊州医疗补助（Medicaid）覆盖、支付方合作以及PRIME临床证据推进PreTRM的商业化进程，Sera Prognostics 2026财年第二季度营收升至30,000美元。
08-14 08:38
Sera Prognostics Announces Publication Of New Subgroup Analysis From PRIME Randomized Controlled Trial, Highlighting Screening Efficiency And Potential Cost Savings In Large Underserved Population
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that P...
07-10 04:09
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population -- SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Com...
07-10 04:05
Sera Prognostics To Participate In A Multi-institutional Research Program That Was Awarded Up To $10.4M By The Advanced Research Projects Agency For Health To Develop A Novel Point-of-care Diagnostic Test Designed To Improve The Safety Of Labor And Delivery
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced its participation in a multi-institutional research program that was awarded up to $10.4 million by the Advanced Res...
06-25 04:14
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
Craig-Hallum Initiates Coverage On Sera Prognostics with Buy Rating, Announces Price Target of $6
Craig-Hallum analyst Bill Bonello initiates coverage on Sera Prognostics (NASDAQ:SERA) with a Buy rating and announces Price Target of $6.
06-05 01:39
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Sera Prognostics Q1 EPS $(0.17), Inline, Sales $14.000K Miss $80.000K Estimate
Sera Prognostics (NASDAQ:SERA) reported quarterly losses of $(0.17) per share which met the analyst consensus estimate. This is a 15 percent increase over losses of $(0.20) per share from the same period last year. The
05-07 04:09
